We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

TECAN GROUP LTD.

Tecan is a provider of automated laboratory instruments and solutions for people working in clinical diagnostics, bas... read more Featured Products: More products

Download Mobile App




Blood Test May Help Identify Fetal Alcohol Spectrum Disorders

By LabMedica International staff writers
Posted on 25 Nov 2016
Print article
Image: The Infinite 200 PRO microplate reader (Photo courtesy of Tecan).
Image: The Infinite 200 PRO microplate reader (Photo courtesy of Tecan).
Fetal alcohol syndrome is a severe form of a spectrum of mental and physical disabilities called fetal alcohol spectrum disorders (FASD) that can affect children's development with long-lasting consequences and a blood test has been developed to predict the severity of disability.

Children and adults affected by FASD may experience a range of symptoms, from physical changes like a small head and subtle differences in facial characteristics to learning difficulties and behavioral issues. In the In the USA and Western Europe, it is estimated that 2% to 5% of school-age children are affected by FASD and in some parts of the world, the number is higher.

A team of collaborating scientists co-led by those at University of California San Diego (La Jolla, CA, USA) looked at birth outcomes for 68 pregnant women enrolled in the study at two perinatal care clinics in western Ukraine. They selected a sample consisting of three groups. The first group of 22 represented moderate to heavily-exposed mothers with an FASD affected child (HEa); the second group of 23 represented moderate to heavily-exposed mothers with an apparently unaffected child, i.e., no facial features, normal head circumference and normal neurobehavioral test scores (HEua); and 23 low alcohol consuming or unexposed mothers with an unaffected child (UE).

Plasma sample quality control analysis and RNA isolation was performed and micro ribonucleic acid (miRNA) profiles were measured using Human miRCURY LNA microRNA real-time polymerase chain reaction (PCR) arrays (Exiqon, Vedbæk, Denmark), which assess 752 unique miRNAs. This platform has been shown in comparison tests, to detect miRNAs in biofluids with greater sensitivity and specificity than other miRNA detection methods. Human Placental Lactogen (hPL) concentration in human plasma was quantitatively determined using a commercially available solid phase sandwich-type enzyme-linked immunoassay (hPL micro-ELISA, Leinco Technologies, Inc, St. Louis, MO, USA). The chromogenic reaction product was quantified spectrometrically using an Infinite m200 at 450nm (Tecan, Männedorf, Switzerland).

The results of the study indicated that moderate to high levels of alcohol exposure during early pregnancy resulted in significant differences in some circulating small RNA molecules called miRNAs in maternal blood. These differences were particularly notable in mothers whose infants showed some physical or neurobehavioral signs of alcohol effects in the first 12 months of life. Plasma placental lactogen content in late pregnancy was not significantly different among HEa, HEua and UE groups.

Christina Chambers, PhD, a professor of pediatrics and co-senior author of the study said, “Although it is generally true that binge-drinking during pregnancy presents the greatest risk, not all women who consume substantial amounts of alcohol in pregnancy will have a child who is clearly affected. That's why we examined specific biomarkers in the mother's blood in the second and third trimester of her pregnancy to determine if they are useful in identifying children who could benefit from early interventions.” The study was published on November 9, 2016, in the journal Public Library of Science ONE.

Related Links:
University of California San Diego
Exiqon
Leinco Technologies
Tecan
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.